Which medications in the drug class Ophthalmics, VEGF Inhibitors are used in the treatment of Diabetic Retinopathy?

Updated: Sep 02, 2021
  • Author: Abdhish R Bhavsar, MD; Chief Editor: Romesh Khardori, MD, PhD, FACP  more...
  • Print
Answer

Ophthalmics, VEGF Inhibitors

These agents can help reduce diabetic macular edema and neovascularization of the disc or retina.

Ranibizumab (Lucentis)

Ranibizumab is a recombinant humanized monoclonal antibody indicated for all forms of diabetic retinopathy (ie, with or without diabetic macular edema). It is also indicated for neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, myopic choroidal neovascularization, and diabetic macular edema. It prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2), thereby suppressing neovascularization, endothelial cell proliferation, and vascular leakage.

Aflibercept intravitreal (Eylea)

Aflibercept is a recombinant decoy VEGF receptor that competes for ligand binding with the endogenous VEGFR 1 and 2 receptors to prevent angiogenesis. It is indicated for all stages of diabetic retinopathy. It is also indicated for neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, and diabetic macular edema.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!